Altimmune, Inc. (ALT) vs Bright Minds Biosciences Inc. (DRUG)

A side-by-side comparison of Altimmune, Inc. and Bright Minds Biosciences Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

Compare

Total return — ALT vs DRUG

growth of $100 · dividends reinvested · last 6y
ALT -83.1% (-25.7%/yr)DRUG +84.4% (+10.7%/yr)DRUG compounded faster over this window
Log scale — wide-divergence pair
1101001kStart $10020222023202420252026$17$184
ALT DRUG

ALT vs DRUG: by the numbers

  • •ALT is the larger company ($519M vs $470M market cap).
  • •Both run net losses; DRUG's is the smaller (0.00% vs -296000.00% net margin).

Metrics side by side

Valuation

MetricALTDRUG
P/S ratio16749.86N/A
P/B ratio1.092.17

Profitability

MetricALTDRUG
Gross margin100.00%0.00%
Operating margin-230460.98%0.00%
Net margin-296000.00%0.00%
ROE-19.35%-8.21%
ROIC-19.47%-13.15%

Growth (annualized)

MetricALTDRUG
Revenue CAGR (5Y)-65.38%N/A
Total return CAGR (5Y)-25.30%6.76%

Frequently asked

How have ALT and DRUG total returns compared?
Over the past 5 years, ALT delivered -25.30% and DRUG delivered 6.76% annualized total return. Past performance doesn't predict future results.

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.